Register | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

The Primary Care Diabetes Society (PCDS) ​12th annual Welsh Conference: ​New horizons in diabetes care​ ​

This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

This promotional webcast series has been developed, organised and funded by Novo Nordisk for healthcare professionals only.

Novo Nordisk treatments may be discussed. Prescribing information will be provided at the meeting.

Type 2 diabetes in primary care: Managing our vulnerable patients through the pandemic and beyond ​

Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk for the purpose of processing your registration only. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055). Calls may be monitored for training purposes.

UK21TSM00013 | Date of preparation: March 2021

This promotional virtual conference has been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee. Lilly Products will be discussed at these meetings, and prescribing information will be available during the conference. Lilly is a registered trademark of Eli Lilly and Company.© 2021 Eli Lilly and Company. All rights reserved.

Prescribing information for Lilly products can be accessed at the following links: Abasaglar® (insulin glargine)Humalog® (insulin glargine)Lyumjev® (insulin lispro) (Please note: Lyumjev is not available in the ROI), Trulicity® (dulaglutide). For more information about Lilly products please visit www.lillydiabetes.co.uk (UK only).

21st Annual Abracadabra Diabetes Nursing Conference

Please note you will be registering for all three meeting dates

This promotional virtual conference has been developed, organised and funded by Lilly in conjunction with the Abracadabra Programme Planning Committee. Lilly Products will be discussed at these meetings, and prescribing information will be available during the conference. Lilly is a registered trademark of Eli Lilly and Company.© 2021 Eli Lilly and Company. All rights reserved.​

Prescribing information for Lilly products can be accessed at the following links: Abasaglar® (insulin glargine)Humalog® (insulin glargine)Lyumjev® (insulin lispro) (Please note: Lyumjev is not available in the ROI), Trulicity® (dulaglutide). For more information about Lilly products please visit www.lillydiabetes.co.uk (UK only).

Adverse events and product complaints should be reported. Reporting forms and further information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store (UK) or www.hpra.ie (ROI). Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on +44 (0) 1256 315000 or Lilly Ireland on +353 (0)1 664 0446 (ROI).

PP-LD-GB-1047 | March 2021

By registering with the site, you can:

Time in range

Is this the new gold standard?

Complete the registration form

30 November 2020

This promotional meeting is organised and funded by Novo Nordisk and Abbott.
Marketing and organisational support has been provided by OmniaMed Communications.
The information presented at this meeting is intended for UK-based healthcare professionals.
Adverse event reporting information and prescribing Information will be available at this meeting.

Prescribing information for Fiasp® (insulin aspart) can be found here.

Prescribing information for Tresiba® (insulin degludec) can be found here.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0845 6005055).
Calls may be monitored for training purposes.

Job code: UK20DI00284; ADC-27961. Date of preparation: October 2020

Thank you for registering.

We look forward to welcoming you online. You will receive a confirmation email shortly and we will send you a reminder email closer to the start of the virtual conference.

Thank you for registering.

We look forward to welcoming you online. You will receive a confirmation email shortly and we will send you a reminder email closer to the start of the webcasts.

Thank you for registering.

We look forward to welcoming you online. You will receive a confirmation email shortly and we will send you a reminder email closer to the start of the broadcast.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.